Whilst rational vertical pathway combination therapy based on dissection of the mechanisms of pathway reactivation has been pivotal to improving upon the results with BRAF inhibitors, the differential efficacy of BRAF inhibition across different BRAF mutant cancers is more likely to be related to the contextual differences, particularly the immune context of the BRAF mutation, rather than differences in the degree of pathway reactivation. Here, BRAF is linked to cancer.